{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/pricing-and-reimbursement-italy-glance#webpage",
"url": "https://www.fortrea.com/insights/pricing-and-reimbursement-italy-glance",
"name": "Pricing and reimbursement in Italy: At a glance",
"description": "This Fortrea case study explores pharmaceutical pricing and reimbursement in Italy through the regulatory and market access framework managed by the Italian Medicines Agency (AIFA). The content explains how the AIFA pricing and reimbursement process evaluates therapeutic value, clinical evidence, comparative benefit, and budget impact to determine reimbursement eligibility for pharmaceutical products. The case study highlights the role of health technology assessment in Italy, including reimbursement pathways for pharmaceuticals, managed entry agreements with AIFA, and pricing negotiations required to support market access within the national healthcare system. It also discusses how pharmaceutical companies can develop an Italy market access strategy by aligning evidence generation, reimbursement planning, and payer expectations with regulatory requirements. By integrating HTA evaluation with pharmaceutical market access planning, the approach supports structured pricing and reimbursement outcomes in Italy"
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Pricing and reimbursement in Italy: At a glance",
"item": "https://www.fortrea.com/insights/pricing-and-reimbursement-italy-glance"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/pricing-and-reimbursement-italy-glance#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/pricing-and-reimbursement-italy-glance#webpage"
},
"headline": "Pharmaceutical Pricing and Reimbursement in Italy and AIFA Market Access Process| Fortrea Case Study",
"description": "TThis Fortrea case study explores pharmaceutical pricing and reimbursement in Italy through the regulatory and market access framework managed by the Italian Medicines Agency (AIFA). The content explains how the AIFA pricing and reimbursement process evaluates therapeutic value, clinical evidence, comparative benefit, and budget impact to determine reimbursement eligibility for pharmaceutical products. The case study highlights the role of health technology assessment in Italy, including reimbursement pathways for pharmaceuticals, managed entry agreements with AIFA, and pricing negotiations required to support market access within the national healthcare system. It also discusses how pharmaceutical companies can develop an Italy market access strategy by aligning evidence generation, reimbursement planning, and payer expectations with regulatory requirements. By integrating HTA evaluation with pharmaceutical market access planning, the approach supports structured pricing and reimbursement outcomes in Italy",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-09/pricing-reimbursement-in-Italy-at-glance.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-09-05",
"dateModified": "2025-09-05",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-09/pricing-reimbursement-in-Italy-at-glance.pdf",
"encodingFormat": "application/pdf"
}
}
]
}